CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting. The study is multi-center, randomized, and placebo-controlled.
Epistemonikos ID: a5aa517d1ef9d6effafef229b6b6e1ab2c391a22
First added on: Oct 06, 2020